GI Oncology
Latest News
Analysis: Actual cancer drug R&D costs are far less than widely publicized sum
Research and development costs for cancer drugs may be far lower than previous estimates, casting doubt on common justifications by drug companies...
Conference Coverage
Minimally invasive esophagectomy may mean less major morbidity
COLORADO SPRINGS – Shorter LOS also seen in ACS-NSQIP analysis
From the Journals
Reduced starting dose of sorafenib for HCC appears safe
The initiation of sorafenib at a reduced dosage may be a safe and reasonable strategy for some patients with hepatocellular carcinoma.
News
FDA approves nivolumab for metastatic CRC
The indication includes patients aged 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal...
From the Journals
VIDEO: Large distal nongranular colorectal polyps were most likely to contain occult invasive cancers
Location and Paris classification had primary importance.
Conference Coverage
Sulindac-erlotinib as chemoprevention for FAP
This study lays an important foundation for effective and feasible chemoprevention of colorectal adenomas in patients with FAP.
From the Journals
Molecular subtypes predicted outcomes in gastric cancer
Genetic details of each cancer may guide treatment.
From the Journals
Blood markers can detect early pancreatic cancer
A test in development is recommended for those at high risk and those newly diagnosed with diabetes.
News
FDA approves new panel to identify mCRC patients for panitumumab treatment
The Food and Drug Administration has approved the Praxis Extended RAS Panel for the identification of metastatic colorectal cancer patients who...
From the Journals
VIDEO: Autoimmune hepatitis with cirrhosis tied to hepatocellular carcinoma
Only 1 of 93 patients who developed HCC in the meta-analysis did not have cirrhosis by the time autoimmune hepatitis was diagnosed.